There is only one innovative pharmaceutical enterprise listed in the second batch of listing application list of science and Technology Innovation Board

[China Pharmaceutical network industry trends] following the release of the first nine companies accepted on March 22, the Shanghai Stock Exchange announced the second batch of eight companies accepted for listing on the science and technology innovation board on the evening of March 27 Surprisingly, there is only one innovative pharmaceutical company on the list - Shenzhen micro core Biotechnology Co., Ltd (hereinafter referred to as "micro core biology") So, what is the origin of this pharmaceutical company? According to the public information, microcellular biology is a well-known innovative pharmaceutical enterprise in China, and its new drug sidabamide has been officially launched It is reported that sidabamide is the first subtype selective histone deacetylase inhibitor in the world, and also the first drug for oral treatment of peripheral T-cell lymphoma in the world The main anti-treatment is recurrent and refractory peripheral T-cell lymphoma The data shows that in 2016, 2017 and 2018, the total sales revenue of xidaban amine products was 85.29 million yuan, 110 million yuan and 146 million yuan respectively, accounting for 85.36 million yuan, 110 million yuan and 147 million yuan respectively in the business revenue of micro core biology from 2016 to 2018; the net profit was 5.39 million yuan, 25.9 million yuan and 31.2762 million yuan respectively The industry pointed out that, after being included in the national medical insurance in 2017, although the price of cedarbenzamine dropped by 30%, the sales increased rapidly, which is also an important reason why the micro core biology can meet the conditions for applying for the science and technology innovation board However, although there is no competitive product in China, the capacity utilization rate in the past three years is less than 40% In this context, the application of sidabamide is also expanding For example, in 2018, the company submitted the listing application of xidaban for the indications of solid tumor breast cancer, and at the same time, the clinical research of xidaban for the indications of AIDS, acute myeloid leukemia, etc In February 2019, the company also reached a cooperation agreement with Cinda bio to explore the safety and tolerance of the combination treatment of cidabamide and Cinda bio in patients with advanced colorectal cancer Industry insiders said that although the market of cedarbenzamine is relatively small at present, the joint treatment of breast cancer is still in the forefront of the current progress This market is relatively large, and some other indications are still in the early experimental stage On March 19, 2019, innovative pharmaceutical companies announced that they had turned their attention to the science and technology innovation board, and had completed the relevant listing guidance work During the guidance period, the micro core biology changed the application board from the main board of Shanghai Stock Exchange to the science and Technology Innovation Board of Shanghai Stock exchange In terms of innovative drugs, the company expects that in 2019, three innovative therapies will be approved for market in China, namely, sieglitazone sodium, a candidate drug for diabetes treatment, theoroni, an anti-tumor drug, and breast cancer treatment, the second indication of sidabamide These three innovative drugs will attract more attention and are expected to get the help of capital In addition, there are five new drugs in clinical status, cs12192, cs12328, cs12629, cs17938 and cs17919, respectively Relevant principals of Shanghai Stock Exchange said that with the gradual normalization of the issuer's declaration, after the second batch of centralized acceptance, Shanghai Stock Exchange will adopt the way of "acceptance is disclosure" to timely announce the acceptance of enterprises The enterprise's acceptance notice and publicity will be disclosed on the website of Shanghai Stock Exchange after the market closing on the day of acceptance In addition, it should be noted that acceptance is only the beginning of the enterprise obtaining the "quasi examination certificate" Next, it needs to go through five steps, such as examination, municipal committee meeting, submission to CSRC, CSRC registration, issuance and listing Therefore, the pharmaceutical enterprises applying should not be careless, but also need to make solid preparations for the subsequent listing.